-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2025-02-11
Values as of: 2025-02-11
The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the StrataQuant(R) Health Care Index. The fund will normally invest at least 90% of its net assets (including investment borrowings) in common stocks that comprise the index. The index is a modified equal-dollar weighted index designed by NYSE to objectively identify and select stocks from the Russell 1000(R) Index in the health care sector that may generate positive alpha relative to traditional passive-style indices through the use of the AlphaDEX(R) selection methodology.
Company Website : www.ftportfolios.com
Currency: USD
Country : USA
Inception Date: 08/05/2007
Primary Benchmark: StrataQuant Health Care TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.61%
Management Expense Ratio: 0.63 %
N/A
N/A
| Symbol | Company Name | Allocation |
|---|---|---|
| RPRX | Royalty Pharma Plc | 2.60 % |
| ITCI | Intracellular Th | 2.58 % |
| THC | Tenet Healthcare Corporation | 2.34 % |
| NTRA | Natera Inc | 2.34 % |
| DOCS | Doximity Inc | 2.31 % |
| ACHC | Acadia Healthcare Company Inc | 2.28 % |
| CAH | Cardinal Health Inc | 2.27 % |
| UHS | Universal Health Services Inc | 2.22 % |
| EXEL | Exelixis Inc | 2.14 % |
| UTHR | United Therapeutics Corporation | 2.12 % |
N/A
N/A
| Symbol | Name | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|
| XLV | Health Care Select Sector SPDR.. | 0.13 % |
-0.21 (-0.14%) |
USD 37.80B |
| FHLC | Fidelity® MSCI Health Care In.. | 0.08 % |
-0.04 (-0.06%) |
USD 2.66B |
| XHE | SPDR® S&P Health Care Equipme.. | 0.35 % |
-1.13 (-1.23%) |
USD 0.21B |
| IDNA | iShares Genomics Immunology an.. | 0.00 % |
+0.20 (+0.90%) |
USD 0.12B |
| SBIO | ALPS Medical Breakthroughs ETF | 0.50 % |
+0.39 (+1.23%) |
USD 0.09B |
| XHS | SPDR® S&P Health Care Service.. | 0.35 % |
-0.33 (-0.33%) |
USD 0.07B |
| HTEC | Robo Global® Healthcare Techn.. | 0.00 % |
+0.06 (+0.20%) |
USD 0.05B |
| BBP | Virtus LifeSci Biotech Product.. | 0.79 % |
+0.44 (+0.72%) |
USD 0.02B |
| BBC | Virtus LifeSci Biotech Clinica.. | 0.79 % |
+0.34 (+1.61%) |
USD 6.89M |
| IHF | iShares U.S. Healthcare Provid.. | 0.43 % |
-0.29 (-0.56%) |
N/A |
N/A
| Market Performance vs. Industry/Classification (Health) | Market Performance vs. Exchange (NYSE Arca) | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 3.50% | 33% | F | 62% | D | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 3.50% | 33% | F | 61% | D- | ||
| Trailing 12 Months | |||||||
| Capital Gain | 3.91% | 57% | F | 43% | F | ||
| Dividend Return | 0.33% | 25% | F | 3% | F | ||
| Total Return | 4.24% | 52% | F | 31% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | 22.04% | 48% | F | 61% | D- | ||
| Dividend Return | 0.91% | 32% | F | 3% | F | ||
| Total Return | 22.95% | 48% | F | 49% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 4.85% | 52% | F | 50% | F | ||
| Dividend Return | 4.99% | 48% | F | 43% | F | ||
| Total Return | 0.14% | 32% | F | 5% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 15.82% | 67% | D+ | 64% | D | ||
| Risk Adjusted Return | 31.54% | 62% | D | 45% | F | ||
| Market Capitalization | 0.92B | 80% | B- | 58% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company has under performed its peers on annual average total returns in the past 5 years.
